|Page (1) of 1 - 01/12/18||email article||print page|
(January 12, 2018)
The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation.
Various pharmaceutical companies such as Novartis AG, Allergan Plc., Janssen Global Services LLC, and Acucela Inc. are engaged in the development drug candidates for the treatment of presbyopia.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/presbyopia-therapeutics-pipeline-analysis/report-sample
Various pharmaceutical companies are developing drug candidates for the treatment of presbyopia, which have shown positive results in different stages of development. For instance, UNR844 showed a statistically significant difference to placebo in distant corrected near vision at all time points measured (from day 8) in the Phase I/II, placebo-controlled, proof-of-concept study carried out in 50 patients daily for 90 days with topical UNR844 and in 25 patients with placebo. At day 90, 82% of participants treated with UNR844 had 20/40 near vision (or 0.30 LogMAR) versus 48% in the placebo group. Near vision of 20/40 allows the majority of near vision tasks in most people.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=presbyopia-therapeutics-pipeline-analysis
Various pharmaceutical companies are involved in manufacturing drugs for the treatment of presbyopia. In January 2017, Alcon, the eye care division of Novartis AG, launched AcrySof IQ PanOptix Toric intraocular lens for presbyopia. The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant achievement in presbyopia treatment. Most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of presbyopia.
Some of the key players developing Novartis AG, Allergan Plc, and ORASIS Pharmaceuticals Ltd.
Presbyopia pipeline analysis
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Company Name: P&S Market ResearchContact Person: Kundan
Address:347 5th Ave. #1402- 210
City: New York City
State: New York
Country: United States
Related Keywords:Business,Health & Medicine,News & Current Affairs,Pharmaceuticals & Biotech,Science,
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter